FOXO4-DRI
Longevity · By Preptide Pro editorial team · Last updated
FOXO4-DRI is a longevity peptide, and it is not FDA-approved. A modified peptide designed to disrupt the FOXO4–p53 interaction in senescent cells. Research so far is in lab and animal models.
Not FDA-approvedChemistry (PubChem)
No matching PubChem compound record was found under this name.
Is FOXO4-DRI FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on FOXO4-DRI?
PubMed lists 19 records for “FOXO4-DRI”, of which 0 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence. | Mol Carcinog | 2026 Sep |
| FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. | Antioxidants (Basel) | 2026 Jul 3 |
| Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. | Naunyn Schmiedebergs Arch Pharmacol | 2026 Jul |
| FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. | Front Bioeng Biotechnol | 2025 |
| The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. | Nat Commun | 2025 Jul 1 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.